Topics

Elevated 68Ga-DOTATATE Activity in Fibrous Cortical Defect.

07:00 EST 7th March 2020 | BioPortfolio

Summary of "Elevated 68Ga-DOTATATE Activity in Fibrous Cortical Defect."

FDG PET/CT was performed for staging in a 15-year-old adolescent girl with cholangiocarcinoma, which showed only mild activity in the tumor but more impressive FDG activity in right femoral fibrous cortical defect without any other hypermetabolic lesions elsewhere. Pathological examination of the resected cholangiocarcinoma revealed significant neuroendocrine differentiation, which lead to subsequent Ga-DOTATATE PET/CT study. Unexpectedly, the same femoral fibrous cortical defect also had increased Ga-DOTATATE activity.

Affiliation

Journal Details

This article was published in the following journal.

Name: Clinical nuclear medicine
ISSN: 1536-0229
Pages:

Links

DeepDyve research library

PubMed Articles [14318 Associated PubMed Articles listed on BioPortfolio]

The Detection of Cardiac Adrenocorticotropic Hormone-Secreting Neuroendocrine Tumor With the Help of 68Ga-DOTATATE PET/CT.

Ectopic adrenocorticotropic hormone Cushing syndrome is a relatively rare condition. We present the case of a 39-year-old man with ectopic adrenocorticotropic hormone Cushing syndrome due to a cardiac...

Combined 68Ga-NOTA-Evans Blue Lymphoscintigraphy and 68Ga-NOTA-RM26 PET/CT Evaluation of Sentinel Lymph Node Metastasis in Breast Cancer Patients.

In this study we applied a strategy to identify sentinel lymph node (SLN) metastasis by combining 68Ga-NOTA-Evans Blue (68Ga-NEB) for SLN mapping and 68Ga-NOTA-RM26 for LN metastasis detection in brea...

Cardiac Metastases in Neuroendocrine Tumors: 68Ga-DOTATATE PET/CT With Cardiac Magnetic Resonance Correlation.

Neuroendocrine tumor (NET) cardiac metastases can be associated with complications including ventricular outflow obstruction, arrhythmias, heart failure, and cardiac arrest, warranting intervention. A...

Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours.

[Lu]DOTATATE prolongs progression free survival (PFS) in metastatic neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled with long duration of therapy and expense sugg...

Broadening horizons with Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety.

The objective of this study was to investigate and present the early results on the efficacy, safety, and quality of life of Ac-DOTATATE targeted alpha therapy (TAT) in patients with advanced, progres...

Clinical Trials [6017 Associated Clinical Trials listed on BioPortfolio]

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the primary tu...

Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients

This is a prospective, Phase 1-2, single center study in a total of 100 subjects with Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of 68Ga-DOTATA...

68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine t...

68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis

68Ga-DOTATATE is a PET radiotracer with high affinity and selectivity for somatostatin receptor 2 (SSTR 2) and is approved clinically for the evaluation of patients with neuroendocrine tum...

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

The Researchers are trying to determine if 68Ga-DOTATATE PET/CT imaging will have a similar accuracy as 18FDG PET/CT in diagnosing cardiac sarcoidosis and if it will be able to do so witho...

Medical and Biotech [MESH] Definitions

Cortical malformations secondary to abnormal cortical maturation after CELL MIGRATION in NEUROGENESIS. This group includes injury to the cortex during later stages of cortical development such as POLYMICROGYRIA and focal cortical dysplasias.

The decrease in neuronal activity (related to a decrease in metabolic demand) extending from the site of cortical stimulation. It is believed to be responsible for the decrease in cerebral blood flow that accompanies the aura of MIGRAINE WITH AURA. (Campbell's Psychiatric Dictionary, 8th ed.)

Rare congenital deformity syndrome characterized by a combination of five anomalies as a result of neural tube defect. The five anomalies are a midline supraumbilical abdominal wall defect (e.g., OMPHALOCELE), a lower STERNUM defect, a congenital intracardiac defect, an anterior DIAPHRAGM defect, and a diaphragmatic PERICARDIUM defect (e.g., PERICARDIAL EFFUSION). Variants with incomplete and variable combinations of the defects are known. ECTOPIA CORDIS; CLEFT LIP; and CLEFT PALATE are often associated with the syndrome.

Cortical malformations secondary to abnormal neuronal and glial CELL PROLIFERATION or APOPTOSIS in NEUROGENESIS. This group includes congenital MICROCEPHALIES; MICROLISSENCEPHALIES, megalencephalies, HEMIMEGALENCEPHALIES and cortical dysplasias with balloon cells.

A disease of bone marked by thinning of the cortex and replacement of bone marrow by gritty fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC). (From Dorland, 28th ed)

Quick Search


DeepDyve research library

Searches Linking to this Article